CXCL9 and neoplasm: Although its anti-proliferative effects may not result from the direct inhibition of the CXCR3 receptor and ligand alterations, the GSK343 inhibitor has been suggested to increase the expression of CXCL9, CXCL10, and CXCL11 in the GBM environment, which enhances NK cell infiltration, thereby inhibiting GBM tumor growth.